Skip to main navigation
×
CLOSE
Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb
®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
News
Publications
Careers
Corporate
Management
Partners
Contact
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
ActivMAb
®
Contact
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
Contact Us
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter
Filter by content type
(-)
News
(20)
Filter by form group
Filter by year
(-)
2023
(20)
Search
News
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
News
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
News
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
News
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
News
Vaccinex Announces Private Placement with Commitments of $5.0 Million
News
Vaccinex New ActivMab® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
News
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
News
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
News
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
News
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Pagination
Previous page
‹‹
Page 2